GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Botanix Pharmaceuticals Ltd (ASX:BOT) » Definitions » Return-on-Tangible-Equity

Botanix Pharmaceuticals (ASX:BOT) Return-on-Tangible-Equity : -68.84% (As of Dec. 2023)


View and export this data going back to 1985. Start your Free Trial

What is Botanix Pharmaceuticals Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Botanix Pharmaceuticals's annualized net income for the quarter that ended in Dec. 2023 was A$-10.93 Mil. Botanix Pharmaceuticals's average shareholder tangible equity for the quarter that ended in Dec. 2023 was A$15.88 Mil. Therefore, Botanix Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was -68.84%.

The historical rank and industry rank for Botanix Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:

ASX:BOT' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -201.64   Med: -102.67   Max: -15.01
Current: -74.66

During the past 13 years, Botanix Pharmaceuticals's highest Return-on-Tangible-Equity was -15.01%. The lowest was -201.64%. And the median was -102.67%.

ASX:BOT's Return-on-Tangible-Equity is ranked worse than
63.52% of 1305 companies
in the Biotechnology industry
Industry Median: -47.16 vs ASX:BOT: -74.66

Botanix Pharmaceuticals Return-on-Tangible-Equity Historical Data

The historical data trend for Botanix Pharmaceuticals's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Botanix Pharmaceuticals Return-on-Tangible-Equity Chart

Botanix Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -201.64 -137.98 -15.01 -102.67 -107.20

Botanix Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -73.97 -138.40 -137.52 -87.91 -68.84

Competitive Comparison of Botanix Pharmaceuticals's Return-on-Tangible-Equity

For the Biotechnology subindustry, Botanix Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Botanix Pharmaceuticals's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Botanix Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Botanix Pharmaceuticals's Return-on-Tangible-Equity falls into.



Botanix Pharmaceuticals Return-on-Tangible-Equity Calculation

Botanix Pharmaceuticals's annualized Return-on-Tangible-Equity for the fiscal year that ended in Jun. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=-9.154/( (4.857+12.222 )/ 2 )
=-9.154/8.5395
=-107.20 %

Botanix Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=-10.934/( (12.222+19.545)/ 2 )
=-10.934/15.8835
=-68.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Botanix Pharmaceuticals  (ASX:BOT) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Botanix Pharmaceuticals Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Botanix Pharmaceuticals's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Botanix Pharmaceuticals (ASX:BOT) Business Description

Traded in Other Exchanges
Address
661 Newcastle Street, D2, LEEDERVILLE, WA, AUS, 6007
Botanix Pharmaceuticals Ltd is a clinical-stage cannabinoid therapeutics company. The company's focus is the development of safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system - Permetrex for direct skin delivery of active pharmaceuticals in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1308 - Plaque Psoriasis, BTX1204 - Atopic Dermatitis, and BTX 1701 - Mild Acne. The majority of Revenue is Derived from Australia.

Botanix Pharmaceuticals (ASX:BOT) Headlines

No Headlines